1,850,653 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Norges Bank

Norges Bank bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,850,653 shares of the medical equipment provider’s stock, valued at approximately $133,414,000. Norges Bank owned 0.82% of Hologic as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of HOLX. General Partner Inc. purchased a new position in shares of Hologic during the fourth quarter valued at $26,000. Groupama Asset Managment boosted its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC grew its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on HOLX shares. Stephens reaffirmed an “overweight” rating and set a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Raymond James reaffirmed an “outperform” rating and issued a $90.00 price target (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Jefferies Financial Group initiated coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Hologic presently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Up 0.7 %

HOLX stock opened at $61.77 on Tuesday. The stock has a market capitalization of $13.86 billion, a price-to-earnings ratio of 19.49, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a 50-day moving average of $65.08 and a two-hundred day moving average of $73.11. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.